Karolinska Development’s portfolio company Promimic’s IPO offering fully subscribed
STOCKHOLM, Sweden, April 25, 2022. Karolinska Development AB (Nasdaq Stockholm: KDEV) today announces that its portfolio company Promimic’s IPO offering was fully subscribed. Promimic is now provided with SEK 80 million before deductions for issue costs, profoundly strengthening the company’s position ahead of its continued growth journey. Trading in the company’s shares is estimated to begin on Friday, April 29 on Nasdaq First North Growth Market.
The offering, which was aimed at both institutional investors and the general public in Sweden, was subscribed for 100 percent.
The estimated first trading day on the Nasdaq First North Growth Market is April 29, 2022, where the shares will be traded under the short name “PRO”.
"The full subscription of the listing issue testifies to Promimic’s strong position and growth strategy, which has enabled the company to defy the uncertain situation in the capital market. With its strengthened financial resources, Promimic will now be able to expand its market investments with a clear focus on securing long-term and high growth, and we are looking forward to taking part in this exciting journey,” says Viktor Drvota, CEO, Karolinska Development.
Karolinska Development's shareholding in Promimic, including indirect ownership via KDev Investments, amounts, after the IPO, to 16.3 percent (1.8 and 14.5 percent, respectively).
For further information, please contact:
Viktor Drvota, CEO, Karolinska Development AB
Phone: +46 73 982 52 02, e-mail: firstname.lastname@example.org
Johan Dighed, General Counsel and Deputy CEO, Karolinska Development AB
Phone: +46 70 207 48 26, e-mail: email@example.com
TO THE EDITORS
Promimic is a growth company that manufactures, markets and sells biomaterials for improved osseointegration (bone healing) to leading companies in the markets for orthopedic and dental implants. The company has its origins in research at Chalmers University of Technology and today has its head office in Mölndal and a sales office in the US. To date, more than 600,000 operations with implants using the Company's technology have been carried out around the world.
About Karolinska Development AB
Karolinska Development AB (Nasdaq Stockholm: KDEV) is a Nordic life sciences investment company. The company focuses on identifying breakthrough medical innovations in the Nordic region that are developed by entrepreneurs and leadership teams. The Company invests in the creation and growth of companies that advance these assets into commercial products that are designed to make a difference to patients' lives while providing an attractive return on investment to shareholders.
Karolinska Development has access to world-class medical innovations at the Karolinska Institutet and other leading universities and research institutes in the Nordic region. The Company aims to build companies around scientists who are leaders in their fields, supported by experienced management teams and advisers, and co-funded by specialist international investors, to provide the greatest chance of success.
Karolinska Development has a portfolio of nine companies targeting opportunities in innovative treatment for life-threatening or serious debilitating diseases.
The Company is led by an entrepreneurial team of investment professionals with a proven track record as company builders and with access to a strong global network.
For more information, please visit www.karolinskadevelopment.com.
AttachmentTo view this piece of content from www.globenewswire.com, please give your consent at the top of this page.
To view this piece of content from ml-eu.globenewswire.com, please give your consent at the top of this page.
About GlobeNewswire by notified
One Liberty Plaza - 165 Broadway
NY 10006 New York
GlobeNewswire by notified is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.
Subscribe to releases from GlobeNewswire by notified
Subscribe to all the latest releases from GlobeNewswire by notified by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from GlobeNewswire by notified
Bavarian Nordic modtager vaccineordre fra europæisk land efter bekræftede tilfælde af abekopper19.5.2022 11:46:42 CEST | pressemeddelelse
KØBENHAVN, Danmark, 19. maj 2022 – Bavarian Nordic A/S (OMX: BAVA) meddelte i dag, at selskabet har indgået en kontrakt med et unavngivet europæisk land vedrørende levering af koppevaccinen IMVANEX® i forbindelse med nye tilfælde af abekopper, der er identificeret i løbet af maj 2022. Det første europæiske tilfælde blev bekræftet den 7. maj 2022 hos en person, der vendte hjem fra en rejse til Nigeria, hvor abekopper er naturligt forekommende. Efterfølgende er der bekræftet mere end 20 tilfælde i England, Portugal og Spanien, og flere formodede tilfælde er ved at blive undersøgt. De fleste infektioner lader til at være sket lokalt i de tre lande. I USA er der bekræftet et enkelt tilfælde hos en rejsende fra Canada, hvor der endnu ikke foreligger bekræftede tilfælde, men adskillige formodede tilfælde er ved at blive undersøgt. Bavarian Nordics koppevaccine er godkendt i USA under navnet JYNNEOS® og i Canada under navnet IMVAMUNE®. I begge lande er godkendelsen udvidet til at omfatte abek
Bavarian Nordic Secures Vaccine Order from European Country After Confirmed Monkeypox Cases19.5.2022 11:46:42 CEST | Press release
COPENHAGEN, Denmark, May 19, 2022 – Bavarian Nordic A/S (OMX: BAVA) announced today that the Company has secured a contract with an undisclosed European country to supply its IMVANEX® smallpox vaccine in response to new cases of monkeypox evolving during May 2022. The first European case was confirmed on May 7, 2022, in an individual who returned from a travel to Nigeria, where monkeypox is endemic. Subsequently, more than 20 cases have been confirmed across England, Portugal and Spain with additional suspected cases currently being investigated. Evidence points to that most of the infections have been acquired locally in these countries. In the US, a single case has been confirmed in a traveler from Canada, where no cases are yet confirmed, but several remain under investigation. Bavarian Nordic’s smallpox vaccine is approved in the U.S. as JYNNEOS® and in Canada as IMVAMUNE®, both places with the approval extended to cover the monkeypox indication. The vaccine is approved in Europe a
XPENG Oslo Experience Store Now Open With XPENG G3i and XPENG P5 Available for Local Test Drives19.5.2022 11:00:00 CEST | Press release
XPENG opens its first Brand Experience Store in the Bjørvika area of downtown Oslo on May 19, 2022.The launch of the fully electric XPENG P5 and XPENG G3i makes Norway the first European country to boast the full range of XPENG EVs. Local test drives are now available to customers.XPENG, in June this year, will be participating in the 35th International Electric Vehicle Symposium (EVS35) 2022, the world’s largest international EV event live from Oslo. OSLO, Norway, May 19, 2022 (GLOBE NEWSWIRE) -- XPENG, a leading electric vehicle manufacturer, is taking the next step in its European expansion by opening its first Norwegian Brand Experience Store in the Bjørvika area of Oslo on May 19. This coincides with the official launch of the brand's two latest models, XPENG G3i and XPENG P5. Establishing a Local Presence XPENG is one of the early adopters of a disruptive retail model in the European market, combining direct, in-store sales with wider agency collaboration. In the Oslo Brand Exper
IBFD launches the 2021 Yearbook on Taxpayers’ Rights19.5.2022 10:00:00 CEST | Press release
Today, IBFD launches the 2021 Yearbook on the Protection of Taxpayers’ Rights (OPTR). The book is a compilation of up-to-date information on the effective protection of taxpayers’ rights. AMSTERDAM, May 19, 2022 (GLOBE NEWSWIRE) -- Prof. Dr Pasquale Pistone and Prof. Dr Philip Baker, Directors of IBFD’s OPTR, will present the Yearbook at the 7th International Conference on Taxpayer Rights, hosted by the Center for Taxpayer Rights, explaining some of the main events and trends that arose last year in the protection of taxpayers’ rights around the world. Click here to watch the video. The OPTR reports on the protection of taxpayers’ fundamental rights around the world. The precise and technical information of the OPTR contains reference to taxpayer bills, conventions and statutes, including their judicial and administrative interpretation, which explore how states apply this protection in practice. The OPTR serves as a unique legal basis for developing further research on the legal remed
Centrient Pharmaceuticals announces its achievement of a significant milestone in the clean production of antibiotics19.5.2022 10:00:00 CEST | Press release
Being the first company to publicly announce 100% PNEC compliance for its entire oral antibiotics product range Rijswijk, The Netherlands, May 19, 2022 (GLOBE NEWSWIRE) -- Summary Centrient Pharmaceuticals reached a significant milestone in the clean production of its antibiotics, with the lowest environmental impact and minimizing the potential contribution to antimicrobial resistanceThe company is the first to publicly announce that Its entire supply chain of oral antibiotics – including its own and supplier manufacturing sites - is fully compliant with the stringent Predicted No Effect Concentration (PNEC) discharge targets set by the AMR Industry AllianceThis achievement demonstrates Centrient Pharmaceuticals’ commitment and leadership in the responsible production of antibiotics. Centrient Pharmaceuticals announces 100% compliance with the stringent Predicted No Effect Concentration (PNEC) discharge targets set by the AMR Industry Alliance for clean manufacturing of its full oral